JP2018534282A5 - - Google Patents

Download PDF

Info

Publication number
JP2018534282A5
JP2018534282A5 JP2018519301A JP2018519301A JP2018534282A5 JP 2018534282 A5 JP2018534282 A5 JP 2018534282A5 JP 2018519301 A JP2018519301 A JP 2018519301A JP 2018519301 A JP2018519301 A JP 2018519301A JP 2018534282 A5 JP2018534282 A5 JP 2018534282A5
Authority
JP
Japan
Prior art keywords
methoxy
chloro
methyl
biphenyl
amino
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2018519301A
Other languages
English (en)
Japanese (ja)
Other versions
JP2018534282A (ja
JP6916783B2 (ja
Filing date
Publication date
Priority claimed from US15/290,167 external-priority patent/US10745382B2/en
Application filed filed Critical
Publication of JP2018534282A publication Critical patent/JP2018534282A/ja
Publication of JP2018534282A5 publication Critical patent/JP2018534282A5/ja
Application granted granted Critical
Publication of JP6916783B2 publication Critical patent/JP6916783B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2018519301A 2015-10-15 2016-10-12 免疫調節剤として有用な化合物 Active JP6916783B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201562242072P 2015-10-15 2015-10-15
US62/242,072 2015-10-15
US15/290,167 US10745382B2 (en) 2015-10-15 2016-10-11 Compounds useful as immunomodulators
US15/290,167 2016-10-11
PCT/US2016/056504 WO2017066227A1 (en) 2015-10-15 2016-10-12 Compounds useful as immunomodulators

Publications (3)

Publication Number Publication Date
JP2018534282A JP2018534282A (ja) 2018-11-22
JP2018534282A5 true JP2018534282A5 (https=) 2019-11-14
JP6916783B2 JP6916783B2 (ja) 2021-08-11

Family

ID=57219000

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2018519301A Active JP6916783B2 (ja) 2015-10-15 2016-10-12 免疫調節剤として有用な化合物

Country Status (20)

Country Link
US (1) US10745382B2 (https=)
EP (1) EP3362443B1 (https=)
JP (1) JP6916783B2 (https=)
KR (1) KR102740320B1 (https=)
CN (1) CN108368090B (https=)
AU (1) AU2016338874A1 (https=)
BR (1) BR112018007381A2 (https=)
CA (1) CA3002008A1 (https=)
CL (1) CL2018000952A1 (https=)
CO (1) CO2018004964A2 (https=)
EA (1) EA201890857A1 (https=)
ES (1) ES2892550T3 (https=)
IL (1) IL258607A (https=)
MA (1) MA42990A (https=)
MX (1) MX2018004347A (https=)
PE (1) PE20181045A1 (https=)
TW (1) TW201726606A (https=)
UY (1) UY36950A (https=)
WO (1) WO2017066227A1 (https=)
ZA (1) ZA201802450B (https=)

Families Citing this family (155)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105705489B (zh) 2013-09-04 2019-04-26 百时美施贵宝公司 用作免疫调节剂的化合物
WO2017070089A1 (en) 2015-10-19 2017-04-27 Incyte Corporation Heterocyclic compounds as immunomodulators
SG10202004618TA (en) 2015-11-19 2020-06-29 Incyte Corp Heterocyclic compounds as immunomodulators
MA44075A (fr) 2015-12-17 2021-05-19 Incyte Corp Dérivés de n-phényl-pyridine-2-carboxamide et leur utilisation en tant que modulateurs des interactions protéine/protéine pd-1/pd-l1
AU2016379372A1 (en) 2015-12-22 2018-08-02 Incyte Corporation Heterocyclic compounds as immunomodulators
AR108396A1 (es) 2016-05-06 2018-08-15 Incyte Corp Compuestos heterocíclicos como inmunomoduladores
WO2017205464A1 (en) 2016-05-26 2017-11-30 Incyte Corporation Heterocyclic compounds as immunomodulators
HUE060256T2 (hu) 2016-06-20 2023-02-28 Incyte Corp Heterociklusos vegyületek mint immunmodulátorok
US10639284B2 (en) 2016-06-27 2020-05-05 Chemocentryx, Inc. Immunomodulator compounds
KR102482673B1 (ko) * 2016-07-05 2022-12-30 광저우 맥시노벨 파마수티컬스 씨오., 엘티디. 방향족 아세틸렌 또는 방향족 에틸렌계 화합물, 그의 중간체, 제조 방법, 약물 조성물 및 용도
EA201990221A1 (ru) * 2016-07-08 2019-06-28 Бристол-Маерс Сквибб Компани 1,3-дигидроксифенильные производные, применимые в качестве иммуномодуляторов
EP3484866B1 (en) 2016-07-14 2022-09-07 Incyte Corporation Heterocyclic compounds as immunomodulators
WO2018044783A1 (en) 2016-08-29 2018-03-08 Incyte Corporation Heterocyclic compounds as immunomodulators
US10144706B2 (en) * 2016-09-01 2018-12-04 Bristol-Myers Squibb Company Compounds useful as immunomodulators
KR20230010826A (ko) 2016-10-14 2023-01-19 프리시젼 바이오사이언시스 인코포레이티드 B형 간염 바이러스 게놈 내의 인식 서열에 대해 특이적인 조작된 메가뉴클레아제
EP3558970B1 (en) 2016-12-20 2021-09-01 Bristol-Myers Squibb Company Compounds useful as immunomodulators
LT3558990T (lt) 2016-12-22 2022-12-27 Incyte Corporation Tetrahidroimidazo[4,5-c]piridino dariniai kaip pd-l1 internalizavimo induktoriai
JP7101678B2 (ja) 2016-12-22 2022-07-15 インサイト・コーポレイション 免疫調節剤としての複素環式化合物
US20180179202A1 (en) 2016-12-22 2018-06-28 Incyte Corporation Heterocyclic compounds as immunomodulators
ES2874756T3 (es) 2016-12-22 2021-11-05 Incyte Corp Derivados de triazolo[1,5-A]piridina como inmunomoduladores
WO2018119221A1 (en) * 2016-12-22 2018-06-28 Incyte Corporation Pyridine derivatives as immunomodulators
EP3567049A4 (en) 2016-12-28 2020-08-26 Green Cross Lab Cell Corporation CHEMERICAL ANTIGENIC RECEPTOR AND NATURAL KILLER CELLS EXPRESSING THE SAME
EP3564237A4 (en) * 2016-12-29 2020-06-10 Shenzhen Chipscreen Biosciences Co., Ltd. UREA COMPOUND AND PRODUCTION METHOD AND USE THEREOF
CN110461829B (zh) 2017-03-27 2023-02-28 百时美施贵宝公司 作为免疫调节剂的取代的异喹啉衍生物
BR102018007822A2 (pt) 2017-04-20 2018-11-06 Gilead Sciences, Inc. composto, métodos para inibir pd-1, pd-l1 e/ou interação de pd-1/pd-l1 e para tratamento de câncer, composição farmacêutica, e, kit para tratamento de ou prevenção de câncer ou uma doença ou condição
WO2018200571A1 (en) 2017-04-25 2018-11-01 Arbutus Biopharma Corporation Substituted 2,3-dihydro-1h-indene analogs and methods using same
WO2019008156A1 (en) * 2017-07-07 2019-01-10 Rijksuniversiteit Groningen INHIBITORS OF PROTEIN / PROTEIN INTERACTION PD-1 / PD-L1
US10919852B2 (en) 2017-07-28 2021-02-16 Chemocentryx, Inc. Immunomodulator compounds
US10392405B2 (en) 2017-08-08 2019-08-27 Chemocentryx, Inc. Macrocyclic immunomodulators
CN109678796B (zh) * 2017-10-19 2023-01-10 上海长森药业有限公司 Pd-1/pd-l1小分子抑制剂及其制备方法和用途
US11649294B2 (en) 2017-11-14 2023-05-16 GC Cell Corporation Anti-HER2 antibody or antigen-binding fragment thereof, and chimeric antigen receptor comprising same
KR102774451B1 (ko) 2017-11-14 2025-02-28 앱클론(주) 항-her2 항체 또는 그의 항원 결합 단편, 및 이를 포함하는 키메라 항원 수용체
KR102162283B1 (ko) * 2017-11-28 2020-10-06 충남대학교 산학협력단 Golga2 유전자 넉아웃 간 섬유화 마우스 모델
KR102162289B1 (ko) * 2017-11-28 2020-10-06 충남대학교 산학협력단 Golga2 유전자 넉아웃 폐 섬유화 마우스 모델
EP3728283B1 (en) 2017-12-20 2023-11-22 Institute of Organic Chemistry and Biochemistry ASCR, V.V.I. 3'3' cyclic dinucleotides with phosphonate bond activating the sting adaptor protein
WO2019123339A1 (en) 2017-12-20 2019-06-27 Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. 2'3' cyclic dinucleotides with phosphonate bond activating the sting adaptor protein
CN109956898B (zh) * 2017-12-22 2021-03-26 上海海雁医药科技有限公司 免疫调节剂及其制法与医药上的用途
CN109988144B (zh) * 2017-12-29 2024-07-05 广州再极医药科技有限公司 芳香乙烯或芳香乙基类衍生物、其制备方法、中间体、药物组合物及应用
KR102738303B1 (ko) * 2018-01-23 2024-12-03 브리스톨-마이어스 스큅 컴퍼니 면역조정제로서 유용한 2,8-디아실-2,8-디아자스피로[5.5]운데칸 화합물
CN110092779B (zh) * 2018-01-29 2022-07-12 广州丹康医药生物有限公司 一种取代的苯基化合物及其应用
CR20200347A (es) 2018-02-13 2020-09-23 Gilead Sciences Inc Inhibidores pd-1/pd-l1
US10568874B2 (en) 2018-02-22 2020-02-25 Chemocentryx, Inc. Indane-amines as PD-L1 antagonists
JP7050165B2 (ja) 2018-02-26 2022-04-07 ギリアード サイエンシーズ, インコーポレイテッド Hbv複製阻害剤としての置換ピロリジン化合物
CN112041312A (zh) * 2018-03-01 2020-12-04 百时美施贵宝公司 用作免疫调节剂的化合物
CN111788193B (zh) * 2018-03-13 2023-04-04 广东东阳光药业有限公司 Pd-1/pd-l1类小分子抑制剂及其在药物中的应用
US12083118B2 (en) 2018-03-29 2024-09-10 Arbutus Biopharma Corporation Substituted 1,1′-biphenyl compounds, analogues thereof, and methods using same
SMT202500157T1 (it) 2018-03-30 2025-05-12 Incyte Corp Composti eterociclici come immunomodulatori
US10870691B2 (en) 2018-04-05 2020-12-22 Gilead Sciences, Inc. Antibodies and fragments thereof that bind hepatitis B virus protein X
TWI833744B (zh) 2018-04-06 2024-03-01 捷克科學院有機化學與生物化學研究所 3'3'-環二核苷酸
TWI818007B (zh) 2018-04-06 2023-10-11 捷克科學院有機化學與生物化學研究所 2'3'-環二核苷酸
TW202005654A (zh) 2018-04-06 2020-02-01 捷克科學院有機化學與生物化學研究所 2,2,─環二核苷酸
US11142750B2 (en) 2018-04-12 2021-10-12 Precision Biosciences, Inc. Optimized engineered meganucleases having specificity for a recognition sequence in the Hepatitis B virus genome
TWI712412B (zh) 2018-04-19 2020-12-11 美商基利科學股份有限公司 Pd‐1/pd‐l1抑制劑
US20190359645A1 (en) 2018-05-03 2019-11-28 Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. 2'3'-cyclic dinucleotides comprising carbocyclic nucleotide
HUE061503T2 (hu) 2018-05-11 2023-07-28 Incyte Corp Tetrahidro-imidazo[4,5-C]piridin-származékok mint PD-L1 immunmodulátorok
EP3804758A4 (en) 2018-05-31 2022-03-02 ONO Pharmaceutical Co., Ltd. BIOMARKERS TO EVALUATE THE EFFECTIVENESS OF AN IMMUNE CHECKPOINT INHIBITOR
WO2019232319A1 (en) 2018-05-31 2019-12-05 Peloton Therapeutics, Inc. Compositions and methods for inhibiting cd73
SG11202012425QA (en) 2018-07-13 2021-01-28 Gilead Sciences Inc Pd-1/pd-l1 inhibitors
WO2020028097A1 (en) 2018-08-01 2020-02-06 Gilead Sciences, Inc. Solid forms of (r)-11-(methoxymethyl)-12-(3-methoxypropoxy)-3,3-dimethyl-8-0x0-2,3,8,13b-tetrahydro-1h-pyrido[2,1-a]pyrrolo[1,2-c] phthalazine-7-c arboxylic acid
CN109305934A (zh) * 2018-08-07 2019-02-05 成都海博锐药业有限公司 苯醚类衍生物及可药用盐、医药上的用途
CN110872275A (zh) * 2018-08-31 2020-03-10 深圳微芯生物科技股份有限公司 作为免疫调节剂的联苯化合物及其用途
TWI855000B (zh) 2018-10-11 2024-09-11 日商小野藥品工業股份有限公司 Sting促效化合物
WO2020086556A1 (en) 2018-10-24 2020-04-30 Gilead Sciences, Inc. Pd-1/pd-l1 inhibitors
US11203591B2 (en) 2018-10-31 2021-12-21 Gilead Sciences, Inc. Substituted 6-azabenzimidazole compounds
WO2020092528A1 (en) 2018-10-31 2020-05-07 Gilead Sciences, Inc. Substituted 6-azabenzimidazole compounds having hpk1 inhibitory activity
AU2019373702A1 (en) 2018-11-02 2021-06-24 Shanghai Maxinovel Pharmaceuticals Co., Ltd. Diphenyl-like compound, intermediate thereof, preparation method therefor, pharmaceutical composition thereof and uses thereof
CN109438263A (zh) * 2018-11-28 2019-03-08 南方医科大学 一种含取代联苯的萘及其应用
WO2020178770A1 (en) 2019-03-07 2020-09-10 Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. 3'3'-cyclic dinucleotides and prodrugs thereof
EP3934757B1 (en) 2019-03-07 2023-02-22 Institute of Organic Chemistry and Biochemistry ASCR, V.V.I. 2'3'-cyclic dinucleotides and prodrugs thereof
WO2020178768A1 (en) 2019-03-07 2020-09-10 Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. 3'3'-cyclic dinucleotide analogue comprising a cyclopentanyl modified nucleotide as sting modulator
KR20210146348A (ko) 2019-03-28 2021-12-03 브리스톨-마이어스 스큅 컴퍼니 종양을 치료하는 방법
WO2020198676A1 (en) 2019-03-28 2020-10-01 Bristol-Myers Squibb Company Methods of treating tumor
CN111747927B (zh) * 2019-03-29 2023-08-18 广州丹康医药生物有限公司 作为免疫调节剂的化合物及其应用
TWI751516B (zh) 2019-04-17 2022-01-01 美商基利科學股份有限公司 類鐸受體調節劑之固體形式
TW202212339A (zh) 2019-04-17 2022-04-01 美商基利科學股份有限公司 類鐸受體調節劑之固體形式
CN112566905B (zh) * 2019-05-10 2024-07-30 上海海雁医药科技有限公司 取代的苯基丙烯基吡啶类衍生物,其制法与医药上的用途
WO2020232256A1 (en) 2019-05-15 2020-11-19 Chemocentryx, Inc. Triaryl compounds for treatment of pd-l1 diseases
EP3972695A1 (en) 2019-05-23 2022-03-30 Gilead Sciences, Inc. Substituted exo-methylene-oxindoles which are hpk1/map4k1 inhibitors
CN111978287A (zh) * 2019-05-23 2020-11-24 中国科学院上海有机化学研究所 一类免疫检查点小分子抑制剂及其制备方法和用途
US20220363760A1 (en) 2019-05-30 2022-11-17 Bristol-Myers Squibb Company Multi-tumor gene signature for suitability to immuno-oncology therapy
WO2020243570A1 (en) 2019-05-30 2020-12-03 Bristol-Myers Squibb Company Cell localization signature and combination therapy
KR20220016155A (ko) 2019-05-30 2022-02-08 브리스톨-마이어스 스큅 컴퍼니 면역-종양학 (i-o) 요법에 적합한 대상체를 확인하는 방법
WO2020248908A1 (zh) * 2019-06-10 2020-12-17 中国科学院广州生物医药与健康研究院 一种双功能免疫调节剂及其在药学上可接受的盐、药物组合物
CN111808086B (zh) * 2019-06-17 2021-12-14 上海海雁医药科技有限公司 杂环取代的苯乙烯基-4-苯基吡啶衍生物及其制法与医药上的用途
WO2020257549A2 (en) 2019-06-20 2020-12-24 Chemocentryx, Inc. Compounds for treatment of pd-l1 diseases
BR112021025888A2 (pt) 2019-07-10 2022-04-26 Chemocentryx Inc Indanos como inibidores de pd-l1
US20220257619A1 (en) 2019-07-18 2022-08-18 Gilead Sciences, Inc. Long-acting formulations of tenofovir alafenamide
KR20220041099A (ko) 2019-08-05 2022-03-31 오노 야꾸힝 고교 가부시키가이샤 면역 체크포인트 저해약의 유효성 판정 바이오마커
JP7665593B2 (ja) 2019-08-09 2025-04-21 インサイト・コーポレイション Pd-1/pd-l1阻害剤の塩
WO2021034804A1 (en) 2019-08-19 2021-02-25 Gilead Sciences, Inc. Pharmaceutical formulations of tenofovir alafenamide
WO2021055994A1 (en) 2019-09-22 2021-03-25 Bristol-Myers Squibb Company Quantitative spatial profiling for lag-3 antagonist therapy
CN112574183B (zh) * 2019-09-29 2022-07-08 南京华威医药科技集团有限公司 一种pd-1抑制剂及其制备方法和用途
DK4037708T3 (da) 2019-09-30 2024-09-30 Gilead Sciences Inc HBV-vacciner og fremgangsmåder til at behandle HBV
PE20221038A1 (es) 2019-09-30 2022-06-17 Incyte Corp Compuestos de pirido[3,2-d] pirimidina como inmunomoduladores
CN114761085A (zh) * 2019-10-04 2022-07-15 百时美施贵宝公司 可用作免疫调节剂的化合物
ES3064674T3 (en) 2019-10-16 2026-04-28 Chemocentryx Inc Heteroaryl-biphenyl amines for the treatment of pd-l1 diseases
JP7736678B2 (ja) 2019-10-16 2025-09-09 ケモセントリックス,インコーポレイティド Pd-l1疾患の処置のためのヘテロアリール-ビフェニルアミド
US20220411499A1 (en) 2019-11-08 2022-12-29 Bristol-Myers Squibb Company LAG-3 Antagonist Therapy for Melanoma
CA3160131A1 (en) 2019-11-11 2021-05-20 Incyte Corporation Salts and crystalline forms of a pd-1/pd-l1 inhibitor
DK4069729T3 (da) 2019-12-06 2025-04-07 Prec Biosciences Inc Optimerede, modificerede meganukleaser med specificitet for en genkendelsessekvens i hepatitis b-virusgenomet
WO2021136354A1 (zh) 2020-01-03 2021-07-08 上海翰森生物医药科技有限公司 联苯类衍生物抑制剂、其制备方法和应用
CN111187172B (zh) * 2020-01-20 2021-10-29 中国药科大学 硝基苯醚类化合物、其制备方法和药物组合物与用途
CN111205196B (zh) * 2020-03-04 2021-04-02 中国科学院昆明植物研究所 一种苯酚类ab环结构化合物及其制备方法和应用
WO2021188959A1 (en) 2020-03-20 2021-09-23 Gilead Sciences, Inc. Prodrugs of 4'-c-substituted-2-halo-2'-deoxyadenosine nucleosides and methods of making and using the same
TW202200136A (zh) 2020-04-10 2022-01-01 日商小野藥品工業股份有限公司 癌治療方法
CN111320606B (zh) * 2020-04-10 2021-07-27 安徽实特医药科技有限公司 苯联吡唑并环类衍生物及其在抗肿瘤药物中的应用
US20230151024A1 (en) 2020-04-10 2023-05-18 Ono Pharmaceutical Co., Ltd. Sting agonistic compound
CN111559981B (zh) * 2020-04-15 2023-08-01 杭州庆正鸿科技有限公司 一种联苯-嘧啶偶联物及其制备方法和应用
KR20230041654A (ko) 2020-05-05 2023-03-24 테온 테라퓨틱스, 인크. 칸나비노이드 수용체 유형 2 (cb2) 조정제 및 그의 용도
CN114075123B (zh) 2020-08-11 2023-06-06 中国人民解放军军事科学院军事医学研究院 苄胺类衍生物及其制备方法与用途
IL300813A (en) 2020-08-28 2023-04-01 Bristol Myers Squibb Co LAG-3 antagonist therapy for hepatocellular carcinoma
AU2021334361A1 (en) 2020-08-31 2023-05-11 Bristol-Myers Squibb Company Cell localization signature and immunotherapy
JP7810700B2 (ja) * 2020-09-09 2026-02-03 ベイジン マキシノベル ファーマシューティカルズ カンパニー リミテッド 芳香族エチレン系化合物、その製造方法、中間体、医薬組成物及びその使用
CN114276328B (zh) * 2020-09-28 2023-09-01 北京康辰药业股份有限公司 作为小分子免疫抑制剂的化合物、其制备方法及其应用
KR20230093282A (ko) 2020-10-23 2023-06-27 브리스톨-마이어스 스큅 컴퍼니 폐암에 대한 lag-3 길항제 요법
CR20230230A (es) 2020-11-06 2023-07-27 Incyte Corp Proceso para hacer un inhibidor de pd-1/pdl1 y sales y formas cristalinas del mismo
WO2022099018A1 (en) 2020-11-06 2022-05-12 Incyte Corporation Process of preparing a pd-1/pd-l1 inhibitor
TW202233615A (zh) 2020-11-06 2022-09-01 美商英塞特公司 Pd—1/pd—l1抑制劑之結晶形式
WO2022120179A1 (en) 2020-12-03 2022-06-09 Bristol-Myers Squibb Company Multi-tumor gene signatures and uses thereof
CN112834643B (zh) * 2020-12-31 2022-03-18 郑州原理生物科技有限公司 测定2,6-二羟基-4-甲基吡啶及2,6-二羟基-3-氰基-4-甲基吡啶的方法
WO2022199578A1 (zh) * 2021-03-22 2022-09-29 南京明德新药研发有限公司 氟代乙烯基联苯衍生物及其应用
CN117858719A (zh) 2021-03-29 2024-04-09 朱诺治疗学股份有限公司 使用检查点抑制剂疗法和car t细胞疗法的组合进行给药和治疗的方法
CN113135895A (zh) * 2021-04-30 2021-07-20 中国药科大学 一种新型联苯类衍生物及其制备方法与医药用途
KR20240004801A (ko) * 2021-05-05 2024-01-11 브리스톨-마이어스 스큅 컴퍼니 면역조절제로서 유용한 락톤 및 락탐 함유 화합물
WO2022241134A1 (en) 2021-05-13 2022-11-17 Gilead Sciences, Inc. COMBINATION OF A TLR8 MODULATING COMPOUND AND ANTI-HBV siRNA THERAPEUTICS
TWI910028B (zh) 2021-06-11 2025-12-21 美商基利科學股份有限公司 Mcl-1抑制劑與抗癌劑之組合
US11931424B2 (en) 2021-06-11 2024-03-19 Gilead Sciences, Inc. Combination MCL-1 inhibitors with anti-body drug conjugates
JP7686091B2 (ja) 2021-06-23 2025-05-30 ギリアード サイエンシーズ, インコーポレイテッド ジアシルグリセロールキナーゼ調節化合物
MX2023014762A (es) 2021-06-23 2024-01-15 Gilead Sciences Inc Compuestos moduladores de diacilglicerol quinasa.
JP7651018B2 (ja) 2021-06-23 2025-03-25 ギリアード サイエンシーズ, インコーポレイテッド ジアシルグリセロールキナーゼ調節化合物
AU2022299051B2 (en) 2021-06-23 2025-03-13 Gilead Sciences, Inc. Diacylglyercol kinase modulating compounds
TW202325306A (zh) 2021-09-02 2023-07-01 美商天恩治療有限公司 改良免疫細胞之生長及功能的方法
CA3224890A1 (en) 2021-10-29 2023-05-04 Bristol-Myers Squibb Company Lag-3 antagonist therapy for hematological cancer
WO2023081730A1 (en) 2021-11-03 2023-05-11 Teon Therapeutics, Inc. 4-hydroxy-2-oxo-1,2-dihydro-1,8-naphthyridine-3-carboxamide derivatives as cannabinoid cb2 receptor modulators for the treatment of cancer
CN114085184B (zh) * 2021-11-17 2023-08-29 中山大学 含环丙烷结构的联苯类衍生物及其制备方法和应用
WO2023097211A1 (en) 2021-11-24 2023-06-01 The University Of Southern California Methods for enhancing immune checkpoint inhibitor therapy
CN114181144B (zh) * 2021-12-06 2023-04-04 浙江工业大学 一种氟代联苯甲基间苯二酚醚类衍生物、其制备方法和应用
US20250144253A1 (en) 2021-12-06 2025-05-08 Helmholtz-Zentrum Dresden-Rossendorf E.V. 3-((3-([1,1'-biphenyl]-3-ylmethoxy)phenoxy)methyl)benzonitrile derivatives and the use thereof
KR20240135661A (ko) 2022-01-26 2024-09-11 브리스톨-마이어스 스큅 컴퍼니 간세포성 암종에 대한 조합 요법
JP7851417B2 (ja) 2022-04-08 2026-04-24 ブリストル-マイヤーズ スクイブ カンパニー 三次リンパ組織様構造の機械学習識別、分類、及び定量化
US20260015356A1 (en) 2022-07-14 2026-01-15 Teon Therapeutics, Inc. Adenosine receptor antagonists and uses thereof
TW202417488A (zh) 2022-08-23 2024-05-01 日商小野藥品工業股份有限公司 雙特異性抗體
CN115368277B (zh) * 2022-09-15 2024-03-29 华侨大学 一种含异羟肟酸结构的联苯类化合物及其应用
WO2024088036A1 (zh) * 2022-10-26 2024-05-02 西安新通药物研究股份有限公司 一种非对称性联苯衍生物及其制备方法与医药用途
EP4638503A1 (en) 2022-12-21 2025-10-29 Bristol-Myers Squibb Company Combination therapy for lung cancer
EP4671242A1 (en) 2023-02-23 2025-12-31 Sunshine Lake Pharma Co., Ltd. PYRIDOPYRIMIDINE DERIVATIVE AND ITS USES
WO2024183756A1 (zh) * 2023-03-07 2024-09-12 上海再极医药科技有限公司 一种含苯环类化合物及其制备方法和应用
WO2024196952A1 (en) 2023-03-20 2024-09-26 Bristol-Myers Squibb Company Tumor subtype assessment for cancer therapy
WO2025240242A1 (en) 2024-05-13 2025-11-20 Gilead Sciences, Inc. Combination therapies with ribavirin
WO2025240246A1 (en) 2024-05-13 2025-11-20 Gilead Sciences, Inc. Combination therapies with ribavirin
WO2025240243A1 (en) 2024-05-13 2025-11-20 Gilead Sciences, Inc. Combination therapies with bulevirtide and an inhibitory nucleic acid targeting hepatitis b virus
WO2025240244A1 (en) 2024-05-13 2025-11-20 Gilead Sciences, Inc. Combination therapies comprising bulevirtide and lonafarnib for use in the treatment of hepatitis d virus infection
WO2025245489A1 (en) 2024-05-24 2025-11-27 Bristol-Myers Squibb Company Treatment of tumors in subjects having fgl-1 positive samples
WO2026035860A1 (en) 2024-08-07 2026-02-12 Teon Therapeutics, Inc. Formulations of adenosine receptor antagonist
CN119504834B (zh) * 2024-11-21 2025-10-17 南开大学 一种以含硅基团为疏水标签的pd-l1蛋白降解剂及其制备方法、药物组合物和应用

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6410690B1 (en) 1995-06-07 2002-06-25 Medarex, Inc. Therapeutic compounds comprised of anti-Fc receptor antibodies
US5811097A (en) 1995-07-25 1998-09-22 The Regents Of The University Of California Blockade of T lymphocyte down-regulation associated with CTLA-4 signaling
US5977117A (en) 1996-01-05 1999-11-02 Texas Biotechnology Corporation Substituted phenyl compounds and derivatives thereof that modulate the activity of endothelin
US5922845A (en) 1996-07-11 1999-07-13 Medarex, Inc. Therapeutic multispecific compounds comprised of anti-Fcα receptor antibodies
JPWO2004007439A1 (ja) 2002-07-10 2005-11-10 住友製薬株式会社 ビアリール誘導体
CA2505322A1 (en) 2002-11-08 2004-05-21 Takeda Pharmaceutical Company Limited Receptor function regulator
EP1603858A2 (en) 2003-03-11 2005-12-14 NeuroSearch A/S Kcnq channel modulating compounds and their pharmaceutical use
JP2005179281A (ja) 2003-12-19 2005-07-07 Sumitomo Pharmaceut Co Ltd ビフェニル化合物
JP4074616B2 (ja) * 2003-12-25 2008-04-09 武田薬品工業株式会社 3−(4−ベンジルオキシフェニル)プロパン酸誘導体
AU2004309271A1 (en) * 2003-12-25 2005-07-14 Takeda Pharmaceutical Company Limited 3-(4-benzyloxyphenyl)propanoic acid derivatives
WO2005080367A1 (en) 2004-02-12 2005-09-01 Pharmagene Laboratories Limited Ep2 receptor agonists
CA2618486A1 (en) 2005-08-09 2007-02-15 Asterand Uk Limited Ep2 receptor agonists
TW200815377A (en) * 2006-04-24 2008-04-01 Astellas Pharma Inc Oxadiazolidinedione compound
AU2008241490B2 (en) 2007-04-16 2011-07-21 Amgen Inc. Substituted biphenyl phenoxy-, thiophenyl- and aminophenylpropanoic acid GPR40 modulators
WO2011082400A2 (en) * 2010-01-04 2011-07-07 President And Fellows Of Harvard College Modulators of immunoinhibitory receptor pd-1, and methods of use thereof
CN105705489B (zh) 2013-09-04 2019-04-26 百时美施贵宝公司 用作免疫调节剂的化合物
ME03398B (me) * 2013-12-17 2020-01-20 Lilly Co Eli Spojevi dimetilbenzojeve kiseline
US9850225B2 (en) * 2014-04-14 2017-12-26 Bristol-Myers Squibb Company Compounds useful as immunomodulators
EA201990221A1 (ru) 2016-07-08 2019-06-28 Бристол-Маерс Сквибб Компани 1,3-дигидроксифенильные производные, применимые в качестве иммуномодуляторов
US10144706B2 (en) 2016-09-01 2018-12-04 Bristol-Myers Squibb Company Compounds useful as immunomodulators

Similar Documents

Publication Publication Date Title
JP2018534282A5 (https=)
JP2023501253A5 (https=)
JP2019531274A5 (https=)
JP2005529092A5 (https=)
JP2020504766A5 (https=)
JP2017518961A5 (https=)
JP2018534282A (ja) 免疫調節剤として有用な化合物
RU2011127232A (ru) Апоптоз-индуцирующие средства для лечения рака и иммунных и аутоиммунных заболеваний
JP2021501179A5 (https=)
CA2479642A1 (en) 4-anilino quinazoline derivatives as antiproliferative agents
JP2016536333A5 (https=)
JP2008509910A5 (https=)
RU2012126987A (ru) Спироиндолциклопропаниндолиноны в качестве модуляторов амрк
CA2476343A1 (en) 2-hydroxy-3-heteroarylindole derivatives as gsk3 inhibitors
JP2012501313A5 (https=)
RU2005119627A (ru) Ингибиторы фосфодиэстеразы 4
JP2010538076A5 (https=)
RU2011127402A (ru) Селективные к bcl-2 агенты, вызывающие апоптоз, для лечения рака и иммунных заболеваний
JP2016503009A5 (https=)
JP2014527082A5 (https=)
RU2011107437A (ru) Ингибиторы кинуренин-3-моноксигеназы
RU2016118619A (ru) Селективно замещенные соединения хинолина
CA2529453A1 (en) Pyrrolidin-1,2-dicarboxylic acid-1-[(4-ethinyl-phenyl)-amide]-2-[(phenyl)-amide] derivative as inhibitors of coagulation factors xa and viia for the treatment of thromboses
JP2015531773A (ja) スルファモイル−アリールアミド及びb型肝炎の治療のための薬剤としてのその使用
JP2012503018A5 (https=)